(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Irampanel |
| Clinical data |
|---|
| ATC code | |
|---|
| Identifiers |
|---|
N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| ChEMBL | |
|---|
| Chemical and physical data |
|---|
| Formula | C18H19N3O2 |
|---|
| Molar mass | 309.369 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3
|
InChI=1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3 Key:QZULPCPLWGCGSL-UHFFFAOYSA-N
|
Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,[1] and the drug was ultimately never marketed.
References
 | Original source: https://en.wikipedia.org/wiki/Irampanel. Read more |
